Immunotherapy

Cutting-edge biological therapies utilizing immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, CTLA-4) to empower the patient’s own immune system to identify, target, and destroy cancer cells.

Immunotherapy represents a transformative paradigm in modern medical oncology. Rather than attacking cancer cells directly with cytotoxic agents, it re-activates the patient’s intrinsic immune machinery to overcome tumor-induced immunosuppression.

Indications & Approaches:

  • Immune Checkpoint Inhibitors: Monoclonal antibodies targeting PD-1 (Pembrolizumab, Nivolumab), PD-L1 (Atezolizumab, Durvalumab), and CTLA-4 (Ipilimumab).
  • Biomarker-Driven Selection: Comprehensive testing for PD-L1 TPS/CPS scores, Microsatellite Instability (MSI-H / dMMR), and Tumor Mutational Burden (TMB).
  • Synergistic Combination Regimens: Chemo-immunotherapy protocols delivering superior progression-free and overall survival rates.
  • Immune-Related Adverse Event (irAE) Management: Specialized clinical surveillance and early intervention for immune-mediated toxicities.
Dr. Chinmayee Agrawal

Consultation with Dr. Chinmayee Agrawal

ECMO Certified Medical Oncologist • Sarvodaya Hospital (Greater Noida West) • Sri Balaji Hospital (Ludhiana)